Related Experiment Video
Updated: May 17, 2026

Characterizing Cell Migration Within Three-dimensional In Vitro Wound Environments
Published on: August 16, 2017
In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component
Christian Albrecht1, Volker Huck, Martin Wehling
1University of Heidelberg, Clinical Pharmacology Mannheim, Maybachstr. 14, 68169 Mannheim, Germany.
Abstract:
Progesterone receptor membrane component type 2 (PGRMC2) is strongly homologous to PGRMC1 which is highly expressed in ovarian cancer and other cancer cells and was claimed to play an important role in chemotherapy resistance. Whereas PGRMC1 has been extensively characterized in in vitro studies, comparably little is known about PGRMC2. To determine PGRMC2's role in ovarian cancer cell proliferation and mobility PGRMC1- and 2-depleted and -overexpressing SKOV-3 cells were generated. In electric cell-substrate impedance sensing studies, PGRMC2 negatively affects SKOV-3 migration rate if overexpressed; oppositely, depletion was associated with an increased migration rate. PGRMC1 had no effect in this assay. These effects were not associated with f-actin regulation or actin cytoskeleton reorganization. Yet, these highly homologous proteins share many properties. Both PGRMC1 and 2 are localized to the endoplasmic reticulum. As PGRMC1 was reported to interact with cytochrome P450 proteins (CYP) binding of two different CYPs to PGRMC2 was tested; a stable interaction of PGRMC2 with CYP3A4 and CYP21A2 was found in human embryonic kidney cells. For both PGRMC types, cell viability assays revealed no significant differences of SKOV-3 survival in overexpressing and depleted cells. PGRMC2 also does not seem to have any influence on the apoptotic effect of cisplatin or the antiapoptotic effect of progesterone which had been reported for PGRMC1. In contrast to PGRMC1, protein levels of PGRMC2 in SKOV-3 cells are reduced by treatment with cisplatin (30-60μM). In conclusion, we show for the first time that PGRMC2 inhibits migration of SKOV-3 ovarian cancer cells in vitro.
Insights
Progesterone receptor membrane component type 2 (PGRMC2) inhibits ovarian cancer cell migration. PGRMC2 overexpression reduced SKOV-3 cell migration, while depletion increased it, revealing its role in ovarian cancer cell mobility.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Progesterone receptor membrane component type 2 (PGRMC2) is homologous to PGRMC1, which is implicated in ovarian cancer chemotherapy resistance.
- Limited in vitro characterization exists for PGRMC2 compared to PGRMC1.
- Understanding PGRMC2's function is crucial for ovarian cancer research.
Purpose of the Study:
- To investigate the role of PGRMC2 in ovarian cancer cell proliferation and migration.
- To compare the functional effects of PGRMC2 with PGRMC1 in SKOV-3 cells.
Main Methods:
- Generated SKOV-3 cells with PGRMC1 and PGRMC2 depletion or overexpression.
- Utilized electric cell-substrate impedance sensing (ECIS) to assess cell migration rates.
- Performed cell viability assays and analyzed protein levels after cisplatin treatment.
Main Results:
- PGRMC2 overexpression significantly inhibited SKOV-3 cell migration, whereas PGRMC2 depletion increased migration.
- PGRMC1 did not affect migration in the ECIS assay.
- No significant differences in cell viability or response to cisplatin/progesterone were observed for PGRMC2, unlike reported effects for PGRMC1.
Conclusions:
- PGRMC2 plays a significant inhibitory role in ovarian cancer cell migration in vitro.
- PGRMC2 protein levels decrease upon cisplatin treatment in SKOV-3 cells.
- PGRMC2's function in ovarian cancer differs from PGRMC1, particularly regarding cell migration.
More Related Videos
06:36A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion
Published on: April 24, 2015
09:57In Vitro Assays to Evaluate the Migration, Invasion, and Proliferation of Immortalized Human First-trimester Trophoblast Cell Lines
Published on: March 5, 2019